The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...

In 2011, to further evaluate the safety of LABAs when used in combination with ICS for the treatment of asthma, the FDA required the manufacturers of LABAs to conduct similar randomized, double-blind, ...

A review of postmarket safety studies by the US Food and Drug Administration (FDA) has found no significant increase in risk for serious asthma-related outcomes when a long-acting β-agonist (LABA) is ...

The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use. As ...

Inhaled corticosteroid–long-acting beta-agonist (ICS-LABA) inhalers are widely prescribed for asthma and chronic obstructive pulmonary disease. ICS-LABAs are largely interchangeable within the class; ...

Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...

The four studies supported the decision to remove the Boxed WARNING for the ICS/LABA class. The labels of medicines that contain both an ICS and LABA retain a Warning and Precaution related to the ...